
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

38549523
CN-22-2263
10.2174/1570159X22666240212141602
Medicine, Neurology, Pharmacology, Neuroscience
Glucose Metabolism and Sex Hormones in Male Patients with Medication-naïve First-episode Schizophrenia: A Large-scale Cross-sectional Study
Xiu Meihong 1
Hao Meng 2
Liu Cai 2
Sun Maodi 3
Lang Xiaoe 2*
1 Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China;
2 Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China;
3 North University of China, Taiyuan, China
* Address correspondence to this author at the Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan, China; E-mail: langxiaoe@yeah.net
16 2 2024
2024
22 13 22632270
17 10 2023
23 11 2023
17 12 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Background

Schizophrenia (SCZ) usually begins in early adult life. The underlying molecular mechanisms of SCZ remain unclear. There is evidence for the involvement of abnormalities in metabolic and endocrine systems in SCZ, even in drug-naïve first-episode schizophrenia patients (DNFES). However, the association between impaired regulation of glucose metabolism and sex hormones was not studied in SCZ. This study aimed to evaluate the interrelationship between sex hormones and high fasting glucose levels in male DNFES patients.

Methods

A total of 99 patients with SCZ were recruited, and fasting glucose, fasting insulin, the insulin resistance index (HOMA-IR), and sex hormones were measured.

Results

We found that some male patients with SCZ had abnormal levels in glucose metabolism parameters and gonadal hormones that were not within the normal range. Linear regression analysis adjusted for age, waist circumference, and body mass index showed that testosterone levels were negatively associated with fasting insulin in male patients (β = -0.21, t = -2.2, p = 0.03).

Conclusion

Our findings confirm the abnormalities in glucose metabolism parameters and gonadal hormones at the onset of the illness in male DNFES patients with SCZ. In addition, there was an interaction effect between abnormal glucose metabolism and sex hormones in male patients.

Keywords

Schizophrenia
first-episode
glucose metabolism
sex hormones
fasting insulin
male patients
==== Body
pmc1 INTRODUCTION

Schizophrenia (SCZ) is a major public health problem affecting 1% of the general population [1]. The exact pathophysiological mechanisms of SCZ remain unclear. Recent literature based on pharmacological studies and genetic research suggests that abnormalities in the neuroendocrine and cardiometabolic systems may interact with early neurodevelopmental defects associated with predisposing genetic aberrations in relation to the molecular etiology of SCZ [2, 3].

Many previous observational studies have reported that type 2 diabetes and other indices of metabolic dysregulation are common in patients with SCZ, resulting in a 15-20-year reduction in life expectancy due to the early onset of cardiometabolic disease and cardiovascular disease [4-9]. The prevalence of type 2 diabetes in the population with SCZ is 3-9 times higher than in the general population [10].

Accumulating data suggest that some components of metabolic syndrome are already present in the early psychosis of SCZ before antipsychotic treatment [11-13]. Indeed, evidence from antipsychotic-naïve patients with SCZ found the presence of a pre-diabetic state or impaired glucose metabolism and diabetes at the onset of SCZ [14, 15]. The higher prevalence of metabolic dysfunction in SCZ may be due to low socioeconomic status, disordered eating and lifestyle, and poor diet, as well as the presence of shared susceptibility genes between SCZ and type 2 diabetes [16, 17]. Insulin signaling has been shown to be involved in the mechanism of the link between SCZ and cardiovascular risk factors [18].

Notably, glucose metabolism and insulin signaling may be regulated by gonadal hormones [19, 20], with age-dependent effects [21-23]. Indeed, studies have found that plasma testosterone (TESTO) is directly associated with insulin sensitivity and that low TESTO levels are associated with an increased risk of type 2 diabetes [24]. In male rats, castration-induced TESTO deficiency significantly reduced insulin sensitivity and led to increased fasting glucose levels [25]. On the other hand, in post-menopausal women and ovariectomized animal models, loss of estrogen has been associated with central obesity, increased insulin resistance, and the development of complications such as type 2 diabetes [26]. The available data support that abnormal levels of gonadal hormones may increase the risk of SCZ development and worsen symptom severity [27, 28].

As abnormal glucose metabolism and endocrine dysfunction are involved in the pathogenesis of SCZ, there is a need to investigate the interrelationship between these abnormalities early in the onset stage of the disease after controlling some confounding factors, such as age, chronicity, antipsychotic medication, etc. On this basis, patients at onset are better suited to test the hypothesis of an intrinsic relationship between endocrine metabolic dysfunction and SCZ compared to chronic patients. Therefore, the purpose of this study was to extend the previous findings on abnormal glucose metabolism and gonadal hormones in patients with SCZ. We hypothesized that there is greater impairment of these markers in SCZ and that there is an interaction between glucose metabolism and sex hormones in SCZ. Therefore, this study would answer the following questions: 1) to conduct an evaluation of glucose metabolism and gonadal hormones in drug-naïve first-episode schizophrenia (DNFES) patients; and 2) to understand the interrelationship between glucose metabolism and sex hormones in male patients, adjusting for age, waist circumference and BMI.

2 METHODS

2.1 Samples

The study protocol was approved by the Ethics Committee of First Hospital of Shanxi Medical University (NO. 2018-K003), and written informed consent was obtained from the patients. We undertook this study between June 1, 2018, and May 31, 2021.

Ninety-nine patients were recruited and met the Diagnostic and Statistical Manual for Mental Disorders (DSM), Fourth Edition (DSM-IV), which was confirmed by two psychiatrists using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P). The SCID-I/P is a semi-structured interview guide for making diagnoses according to the diagnostic criteria published in the American Psychiatric Association’s DSM, which has been shown to be reliable and valid in China [29]. They were all drug-naïve first-episode patients with a duration of illness < 5 years based on a previous study [30]. The inclusion criteria included: 1) first episode of psychosis and medication-naïve status; 2) 18-45 years of age; 3) duration of illness not more than five years; and (4) male. Patients also need to meet the following exclusion criteria: (1) autism spectrum disorders; (2) mental retardation; (3) abuse or substance dependence; (4) diagnosable organic brain disease or major medical somatic comorbidities (e.g., cancer, diabetes, cerebrovascular disease, or hypertension); (5) any history of endocrine disorder; (6) signs of hyperandrogenism, such as acne and hirsutism; and (7) currently receiving hormone replacement therapy or hormonal contraceptives.

2.2 Measurements of Glucose Metabolism Parameters

Fasting venous blood samples (5 ml) were drawn from all patients into BD Vacutainer Rapid Serum Tubes between 7:30 AM and 8:30 AM and were centrifuged for 10 min at 4,000 g. Serum levels of glucose and gonadal hormone were quantified from fresh blood samples following centrifugation. The biochemical analysis was carried out in duplicate at the hospital laboratory by three technicians blind to the clinical status of the participants.

Serum glucose (FBG) levels were measured using an enzymatic method and by HITACHI 7600 automatic biochemistry analyzer (Hitachi, Japan). The normal range for an FBG level was 3.9-6.1 mmol/L in China. Serum insulin (FINS) levels and glycated hemoglobin (HbA1c) levels were measured using commercially available kits (Roche Diagnostics, GmbH, Mannheim, Germany). Insulin was analyzed on Cobas 6000 (Roche), and HbA1c was determined on the Roche Cobas 501. The normal ranges for the levels of insulin and HbA1c were from 2.6 to 24.9 μU/mL and from 4.8% to 5.9%, respectively. Insulin resistance index HOMA-IR was determined by using the homeostatic model of assessment (HOMA) as the product of fasting serum insulin levels and fasting serum glucose levels divided by 22.5.

2.3 Measurements of Gonadal Hormone Levels

Serum levels of sex hormone indicators, including estradiol (E2), follicular-stimulating hormone (FSH), progesterone (PROG), luteinizing hormone (LH) and TESTO, were measured using the chemiluminescence immunoassays by an automated Beckman UniCel DxI800A analyzer (Beckman Coulter, Brea, CA, USA). The normal ranges for FSH, PROG, LH, TESO and E2 were 1.27-19.26 mIU/ml, 0.45-6.55 nmol/L, 1.24-8.62 mIU/ml, 6.07-27.1 nmol/L and 14-55 pmol/L.

2.4 BMI and Waist Circumference Measurements

Weight and height were measured in a standardized fashion to calculate BMI (weight over squared height, Kg/m2). Height was measured to the nearest millimeter, with the subjects barefooted and standing upright. Weight was measured with an electronic scale, and patients were weighed in light indoor clothing.

Waist circumference was measured at the end of normal expiration at the umbilical waist (horizontal at the umbilicus).

2.5 Statistical Analysis

Statistical analysis was performed in SPSS, version 22.0. Statistical significance p was fixed to 0.05.

The categorical variable was reported as numbers with percentages, and the normally distributed numerical variable was reported as mean ± standard deviation. Nonnormally distributed numerical variable was reported with median and interquartile ranges (IQRs). Since most of the data were not normally distributed, non-parametric tests were generally used in this study.

Spearman-Rho correlation analysis was performed for the calculation of correlations between glucose metabolism parameters and gonadal hormones in male patients. Further linear regression analyses were used to confirm the association between these parameters after controlling for age, waist circumference and BMI. The Bonferroni corrections were conducted to adjust for multiple comparisons.

3 RESULTS

The demographic, glucose metabolism parameters, sex hormone levels and the normal reference ranges are shown in Table 1. We identified the number of patients with abnormal glucose metabolism parameters as follows: n = 1 for HbA1c, n = 6 for FINS and n = 42 for HOMA-R. In addition, the number of patients who had abnormal sex hormone levels was n = 26 for E2 and n = 3 for LH.

Correlation analysis showed significant associations between age or onset age and FBG (r = 0.28, p = 0.005; r = 0.28, p = 0.006), between waist circumference and fasting FINS (r = 0.44, p < 0.001) and HOMA-IR (r = 0.45, p < 0.001), as well as between BMI and fasting FINS (r = 0.45, p < 0.001) and HOMA-IR (r = 0.44, p < 0.001) in male patients with SCZ.

Spearman correlation analysis showed that there were significant negative correlations of TESTO levels with FBG (r = -0.23, p = 0.025), FINS (r = -0.34, p < 0.001), and HOMA-IR (r = -0.35, p < 0.001) in male patients (Table 2). In addition, PROG levels were negatively associated with FINS (r = -0.29, p = 0.004) and HOMA-IR (r = -0.28, p = 0.005). After Bonferroni corrections, the associations between FBG and HOMA-IR, as well as FINS, were statistically significant (all pBonferroni < 0.05). Moreover, regression analysis also supported the association after controlling for age, BMI, and waist circumference and found that TESTO levels were significantly associated with fasting FINS levels in male patients (β = -0.21, t = -2.2, p = 0.03) but not with PROG (β = -0.08, t = -0.84, p = 0.40) (Table 3).

4 DISCUSSION

We found male DNFES patients with SCZ had abnormal levels of glucose metabolism parameters and sex hormones in the early stage of the disease. Additionally, in male patients, TESTO levels were negatively correlated with fasting insulin levels and HOMA-IR. To our present knowledge, it is the first study to explore the interrelationship between glucose metabolism and hormones in a large-scale sample of male DNFES patients in China.

Our findings of abnormal glucose metabolism parameters and sex hormone levels in male DNFES patients with SCZ were consistent with previous studies [31-33]. In particular, we found more patients with abnormal levels of fasting FINS and higher HOMA-IR. Insulin receptors have been reported to be widely distributed in the hippocampus, cerebral cortex, and hypothalamus [34]. Insulin resistance was found to be significantly associated with polygenic risk for SCZ, independent of age, ethnicity, lifestyle, and clinical factors [35]. When peripheral insulin levels are elevated, insulin levels in the cerebrospinal fluid are increased through the blood-brain barrier, which may lead to insulin resistance in the brain [36]. In addition, functional reductions in insulin signaling were also observed in patients with SCZ using the post-mortem brain [37, 38]. Recent data has also demonstrated impaired glia or neuronal insulin signal transduction in extracellular vesicles from the brain in SCZ [39, 40], as well as deleterious effects of impaired glucose/lactate supply on cerebral connectivity and myelinization [41-43].

Our study also demonstrates a disturbance of sex hormones, such as E2 and LH, in some male patients with SCZ. During adolescence, there are dramatic changes in the activation and amplification of the pulsed release of LH in boys and a rapid increase in circulating E2 [44]. The estrogen hypothesis postulates a protective role of E2 on the development and increased severity of SCZ [28, 45]. Estrogens have direct neuroprotective actions by impacting the levels of major neurotransmitter systems relevant to SCZ, such as dopamine signaling, glutamatergic, and serotonergic systems, as well as the density of receptors for these neurotransmitter systems [46-49]. Furthermore, hippocampal neurogenesis, such as the formation of dendritic spines and new neuronal connections, also depends on E2 levels in the hippocampus [50]. The density of dendritic spines in the hippocampus alters throughout the menstrual cycle, with the highest density occurring when E2 peaks [51]. Thus, when E2 levels are disturbed, it may lead to alterations in brain structure, including the number of neurons, neural plasticity and modifications in the bioenergetics of the brain. Recent studies have also reported that E2 deprivation induces mitochondrial dysfunctions and hippocampal synapse disruption in the brain, which may induce the decline of cognitions [52, 53] and further contribute to clinical symptoms in patients with SCZ.

This study also found that fasting insulin levels, insulin resistance index, and TESTO levels were negatively correlated in DNFES patients. The role of TESTO in the pathogenesis of SCZ is much less understood than the effects of estrogens. There was evidence that TESTO levels were lower in male patients with SCZ compared to sex- and age-matched controls [27, 54]. Under normal physiological conditions, TESTO plays a fundamental role in the maintenance of insulin sensitivity, insulin concentrations and islet β-cell function in men [24]. Studies in cultured adipocyte cells found that TESTO increased the phosphorylation of insulin receptor substrates-1 (Chen et al. 2006). Additionally, TESTO activates the cAMP-dependent protein kinase pathway by binding to the receptors in pancreatic islet β-cells and enhancing the regulation of the receptors by glucagon-like peptide-1 [55]. In preclinical studies, chronic high-calorie diet-induced obese male mice developed peripheral insulin resistance through increased adipose tissue accumulation and reduced blood TESTO levels [56-59]. Studies from men with hypogonadism and low TESTO levels have shown that insulin resistance develops over time, although patients do not show insulin resistance at the onset [60]. In particular, a retrospective study of 150 obese men by Souteiro et al. reported that 52% of patients were TESTO deficient and that their TESTO levels were negatively correlated with the insulin resistance index [61]. In the brain, studies show that TESTO plays a crucial role in brain development by influencing synaptic connectivity and neuronal differentiation [62, 63]. More importantly, TESTO also influences dopaminergic, glutamatergic and GABAergic neurotransmission systems, which contribute to the pathophysiology of SCZ [62]. All these studies support that abnormal TESTO signaling may serve as a risk factor for disturbed glucose metabolism and psychotic symptoms in male patients with SCZ.

Notably, although some patients with SCZ in our present study were abnormal in the glucose metabolism parameters and gonadal hormone levels, however, the average or median values of these biomarkers were within normal ranges. These findings that these biomarkers were not altered in patients are consistent with previous studies [31, 32], possibly because all patients were young patients in their first episode, with a median age of the patients 24 years.

This study had several limitations. First, the cross-section design limited the information available to infer the causal relationship between glucose metabolism parameters and hormones. Further longitudinal follow-up studies, including a large sample of DNFES patients are warranted to address this issue in the future by measuring hormone levels at appropriate times of the day and longitudinal evaluation in a substantial number of patients with SCZ. Second, we did not recruit a normal control group, and the comparisons with normal controls would give more information on our results. However, we could compare the levels of these biomarkers with the normal reference range in the general population. Third, clinical symptoms were not assessed using the Positive and Negative Syndrome Scales (PANSS), and we cannot analyze the associations between the severity of symptoms and insulin resistance. Additionally, the effects of diet and lifestyle on the relationship between glucose metabolism and sex hormones were not included in the statistical analyses. These data needed to be collected in a future study. Fourth, our study only recruited male patients with SCZ, and further investigation should also be performed to examine whether there was an interrelationship between glucose metabolism and gonadal hormones among female patients.

CONCLUSION

This study demonstrates that male DNFES patients had abnormal glucose metabolism parameters and gonadal hormone levels. Fasting insulin was negatively associated with levels of TESTO in men, suggesting a close relationship between glucose metabolism and hormones in male patients at the onset of SCZ. Our study focused on the interrelationship between metabolic and endocrine signaling pathways related to SCZ, providing important translational insights into the complex and multifaceted pathophysiological mechanism of SCZ. However, considering that these biomarkers are easily influenced by other demographic and clinical confounders, as well as our cross-sectional design, we did not draw a causal conclusion about the relationship between glucose metabolism and sex hormone levels and further studies with a longitudinal design are warranted to better understand the impact of sex hormones on metabolic markers in the early stage of SCZ.

ACKNOWLEDGEMENTS

Declared none.

AUTHOR’S CONTRIBUTIONS

MX, CL and MH were responsible for study design, statistical analysis and manuscript preparation. MX, CL, MS and MH were responsible for recruiting the patients, performing the clinical rating and collecting the clinical data. XL and MH were evolving the ideas and editing the manuscript. XL and MX were involved in writing the protocol and co-wrote the paper. All authors have contributed to and approved the final manuscript.

LIST OF ABBREVIATIONS

DNFES Drug-naïve First-episode Schizophrenia Patients

FSH Follicular-stimulating Hormone

IQRs Interquartile Ranges

LH Luteinizing Hormone

PANSS Positive and Negative Syndrome Scales

SCZ Schizophrenia

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Ethics Committee of First Hospital of Shanxi Medical University, China, approval number 2018-K003.

HUMAN AND ANIMAL RIGHTS

The work on patients was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

CONSENT FOR PUBLICATION

Written informed consent was obtained from the patients.

AVAILABILITY OF DATA AND MATERIALS

The data that support the findings of this study are available from the corresponding author [XL], upon reasonable request.

FUNDING

The study was funded by a Nation Funded Project for Regional Science and Technology Development (Basic Research) Project (No. YDZJSX2022A064), and a Research Project Funded by Special Grant 136 of First Hospital of Shangxi Medical University (No. Y2022136006). The funding for this study had no further role in study design, data analysis, and the decision to submit the paper for publication.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

SUPPLEMENTARY MATERIAL

Supplementary material is available on the publisher’s website along with the published article.

Table 1 The demographic, glucose metabolism parameters, and sex hormone levels in patients with schizophrenia.

-	Male Patients
n = 99	Normal Reference Range	
Age(ys), median (IQR)	23.00(19.00,30.00)	-	
Course(ms), median (IQR)	24.00(6.00,51.00)	-	
Onset age(ys), median (IQR)	20.92(17.33,28.00)	-	
Waist(cm), median (IQR)	79.9(76.6,86.6)	< 85	
BMI(kg/m2), mean ± SD	23.14 ± 3.34	18.5-23.9	
Education(ys), median (IQR)	12.00(10.00,15.00)	-	
FBG, mean ± SD	5.23 ± 0.36	3.9-6.1	
FINS, median (IQR)	9.71(5.80,13.97)	2.6-24.9	
HOMA-IR, median (IQR)	2.36(1.37,3.18)	< 2.69	
HbA1c(%), mean ± SD	5.27 ± 0.31	4.8-5.9	
E2, median (IQR)	103.00(78.00,124.00)	73-173	
FSH, median (IQR)	3.60(2.60,5.30)	1.27-19.26	
PROG, median (IQR)	1.81(1.14,2.40)	0.45-6.55	
LH, median (IQR)	3.60(2.55,4.82)	1.24-8.62	
TESTO, mean ± SD	13.79 ± 4.62	6.07-27.1	
Abbreviations: ys years, ms months, BMI body mass index, FBG fasting blood glucose, FINS fasting insulin, HOMA-IR insulin resistance index, E2 estradiol, FSH follicular-stimulating hormone, PROG progesterone, LH luteinizing hormone, and TESTO testosterone, PRL prolactin.

Table 2 Associations between glucose metabolism parameters and sex hormones in male patients.

-	-	E2	FSH	PROG	LH	TESTO	
FBG	r	-0.067	-0.020	0.002	-0.063	-0.225	
p	0.513	0.846	0.981	0.533	0.025	
HbA1c	r	-0.118	-0.104	-0.081	-0.010	0.024	
p	0.245	0.308	0.423	0.923	0.812	
FINS	r	0.000	0.062	-0.288	0.107	-0.340	
p	0.997	0.541	0.004	0.290	<0.001	
HOMA-IR	r	-0.012	0.062	-0.280	0.090	-0.351	
p	0.910	0.543	0.005	0.374	<0.001	
Abbreviations: FBG fasting blood glucose, HbA1c glycated hemoglobin, FINS Fasting serum insulin, HOMA-IR insulin resistance index, E2 estradiol, FSH follicular-stimulating hormone, PROG progesterone, LH luteinizing hormone, and TESTO testosterone.

Table 3 Linear regression of the factors related to fasting insulin in male patients with schizophrenia.

Sex	-	Unstandardized Coefficients	Standardized Coefficients	t	p	
B	Sth. Error	Beta	
Male	(Constant)	-5.476	6.022	-	-0.909	0.366	
PROG	-0.518	0.614	-0.081	-0.844	0.401	
TESTO	-0.283	0.129	-0.208	-2.192	0.031	
Waist	4.995	3.151	0.216	1.585	0.116	
BMI	0.389	0.258	0.207	1.503	0.136	
Abbreviations: E2 estradiol, PROG progesterone, BMI body mass index, and TESTO testosterone.
==== Refs
REFERENCES

1 Pedersen C.B. Mors O. Bertelsen A. Waltoft B.L. Agerbo E. McGrath J.J. Mortensen P.B. Eaton W.W. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 2014 71 5 573 581 10.1001/jamapsychiatry.2014.16 24806211
2 Barnett R. Schizophrenia. Lancet 2018 391 10121 648 10.1016/S0140-6736(18)30237-X 29617256
3 Nguyen K.D. Amerio A. Aguglia A. Magnani L. Parise A. Conio B. Serafini G. Amore M. Costanza A. Microglia and other cellular mediators of immunological dysfunction in schizophrenia: A narrative synthesis of clinical findings. Cells 2023 12 16 2099 10.3390/cells12162099 37626909
4 Mitchell A.J. Vancampfort D. Sweers K. van Winkel R. Yu W. De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: A systematic review and meta-analysis. Schizophr. Bull. 2013 39 2 306 318 10.1093/schbul/sbr148 22207632
5 Correll C.U. Solmi M. Veronese N. Bortolato B. Rosson S. Santonastaso P. Thapa-Chhetri N. Fornaro M. Gallicchio D. Collantoni E. Pigato G. Favaro A. Monaco F. Kohler C. Vancampfort D. Ward P.B. Gaughran F. Carvalho A.F. Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017 16 2 163 180 10.1002/wps.20420 28498599
6 Li S. Chen D. Xiu M. Li J. Zhang X.Y. Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia: A case control study. J. Psychiatr. Res. 2021 134 39 47 10.1016/j.jpsychires.2020.12.035 33360223
7 Li S. Gao Y. Lv H. Zhang M. Wang L. Jiang R. Xu C. Wang X. Gao M. He Y. Li J. Li W.D. T4 and waist: Hip ratio as biomarkers of antipsychotic-induced weight gain in Han Chinese inpatients with schizophrenia. Psychoneuroendocrinology 2018 88 54 60 10.1016/j.psyneuen.2017.11.010 29175720
8 Li S. Xu C. Tian Y. Wang X. Jiang R. Zhang M. Wang L. Yang G. Gao Y. Song C. He Y. Zhang Y. Li J. Li W.D. TOX and ADIPOQ gene polymorphisms are associated with antipsychotic-induced weight gain in han chinese. Sci. Rep. 2017 7 1 45203 10.1038/srep45203 28327672
9 Zhu M.H. Liu Z.J. Hu Q.Y. Yang J.Y. Jin Y. Zhu N. Huang Y. Shi D.H. Liu M.J. Tan H.Y. Zhao L. Lv Q.Y. Yi Z.H. Wu F.C. Li Z.Z. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine resistant treatment refractory schizophrenia: A 12-week randomized, double-blind, placebo controlled trial. Mil. Med. Res. 2022 9 1 59 10.1186/s40779-022-00420-0 36253804
10 Rajkumar A.P. Horsdal H.T. Wimberley T. Cohen D. Mors O. Børglum A.D. Gasse C. Endogenous and antipsychotic related risks for diabetes mellitus in young people with schizophrenia: A danish population-based cohort study. Am. J. Psychiatry 2017 174 7 686 694 10.1176/appi.ajp.2016.16040442 28103712
11 Chen Y.Q. Li X.R. Zhang L. Zhu W.B. Wu Y.Q. Guan X.N. Xiu M.H. Zhang X.Y. Therapeutic response is associated with antipsychoticinduced weight gain in drug naive first episode patients with schizophrenia. J. Clin. Psychiatry 2021 82 3 20m13469 10.4088/JCP.20m13469 34004092
12 Liu H. Yu R. Gao Y. Li X. Guan X. Thomas K. Xiu M. Zhang X. Antioxidant enzymes and weight gain in drug-naive first-episode schizophrenia patients treated with risperidone for 12 weeks: A prospective longitudinal study. Curr. Neuropharmacol. 2022 20 9 1774 1782 10.2174/1570159X19666210920090547 34544343
13 Liu H. Liu H. Jiang S. Su L. Lu Y. Chen Z. Li X. Li X. Wang X. Xiu M. Zhang X. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: A prospective longitudinal study. Curr. Neuropharmacol. 2022 20 9 1793 1803 10.2174/1570159X19666211111123918 34766896
14 Greenhalgh A.M. Gonzalez-Blanco L. Garcia-Rizo C. Fernandez-Egea E. Miller B. Arroyo M.B. Kirkpatrick B. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic naïve patients with nonaffective psychosis. Schizophr. Res. 2017 179 57 63 10.1016/j.schres.2016.09.026 27743650
15 Garcia-Rizo C. Fernandez-Egea E. Oliveira C. Meseguer A. Cabrera B. Mezquida G. Bioque M. Penades R. Parellada E. Bernardo M. Kirkpatrick B. Metabolic syndrome or glucose challenge in first episode of psychosis? Eur. Psychiatry 2017 41 1 42 46 10.1016/j.eurpsy.2016.10.001 28049080
16 Mizuki Y. Sakamoto S. Okahisa Y. Yada Y. Hashimoto N. Takaki M. Yamada N. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int. J. Neuropsychopharmacol. 2021 24 5 367 382 10.1093/ijnp/pyaa097 33315097
17 Pillinger T. Beck K. Gobjila C. Donocik J.G. Jauhar S. Howes O.D. Impaired glucose homeostasis in first-episode schizophrenia. JAMA Psychiatry 2017 74 3 261 269 10.1001/jamapsychiatry.2016.3803 28097367
18 Agarwal S.M. Caravaggio F. Costa-Dookhan K.A. Castellani L. Kowalchuk C. Asgariroozbehani R. Graff-Guerrero A. Hahn M. Brain insulin action in schizophrenia: Something borrowed and something new. Neuropharmacology 2020 163 107633 10.1016/j.neuropharm.2019.05.010 31077731
19 Bastemir M. Akin F. Emral R. Alkis E. Impact of insulin sensitivity in relationship with prolactin and thyroid stimulating hormone. Exp. Clin. Endocrinol. Diabetes 2007 115 4 257 260 10.1055/s-2007-960492 17479443
20 Li J. Rice M.S. Huang T. Hankinson S.E. Clevenger C.V. Hu F.B. Tworoger S.S. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia 2018 61 12 2549 2560 10.1007/s00125-018-4733-9 30306190
21 Wagner R. Heni M. Linder K. Ketterer C. Peter A. Böhm A. Hatziagelaki E. Stefan N. Staiger H. Häring H.U. Fritsche A. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol. 2014 51 1 71 78 10.1007/s00592-013-0493-7 23836327
22 Le T.N. Celi F.S. Wickham E.P. III Thyrotropin levels are associated with cardiometabolic risk factors in euthyroid adolescents. Thyroid 2016 26 10 1441 1449 10.1089/thy.2016.0055 27599541
23 Lundbäck V. Ekbom K. Hagman E. Dahlman I. Marcus C. Thyroid-stimulating hormone, degree of obesity, and metabolic risk markers in a cohort of swedish children with obesity. Horm. Res. Paediatr. 2017 88 2 140 146 10.1159/000475993 28614818
24 Pintana H. Chattipakorn N. Chattipakorn S. Testosterone deficiency, insulin-resistant obesity and cognitive function. Metab. Brain Dis. 2015 30 4 853 876 10.1007/s11011-015-9655-3 25703239
25 Xia F. Xu X. Zhai H. Meng Y. Zhang H. Du S. Xu H. Wu H. Lu Y. Castration-induced testosterone deficiency increases fasting glucose associated with hepatic and extra-hepatic insulin resistance in adult male rats. Reprod. Biol. Endocrinol. 2013 11 1 106 10.1186/1477-7827-11-106 24238614
26 Gupte A.A. Pownall H.J. Hamilton D.J. Estrogen: an emerging regulator of insulin action and mitochondrial function. J. Diabetes Res. 2015 2015 1 9 10.1155/2015/916585 25883987
27 Brzezinski-Sinai N.A. Brzezinski A. Schizophrenia and sex hormones: What is the link? Front. Psychiatry 2020 11 693 10.3389/fpsyt.2020.00693 32760302
28 Gogos A. Ney L.J. Seymour N. Van Rheenen T.E. Felmingham K.L. Sex differences in schizophrenia, bipolar disorder, and post‐traumatic stress disorder: Are gonadal hormones the link? Br. J. Pharmacol. 2019 176 21 4119 4135 10.1111/bph.14584 30658014
29 Phillips M.R. Zhang J. Shi Q. Song Z. Ding Z. Pang S. Li X. Zhang Y. Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: An epidemiological survey. Lancet 2009 373 9680 2041 2053 10.1016/S0140-6736(09)60660-7 19524780
30 Lieberman J.A. Phillips M. Gu H. Stroup S. Zhang P. Kong L. Ji Z. Koch G. Hamer R.M. Atypical and conventional antipsychotic drugs in treatment naive first episode schizophrenia: A 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 2003 28 5 995 1003 10.1038/sj.npp.1300157 12700715
31 Zhang X. Yang M. Du X. Liao W. Chen D. Fan F. Xiu M. Jia Q. Ning Y. Huang X. Wu F. Soares J.C. Cao B. Wang L. Chen H. Glucose disturbances, cognitive deficits and white matter abnormalities in first episode drug naive schizophrenia. Mol. Psychiatry 2020 25 12 3220 3230 10.1038/s41380-019-0478-1 31409883
32 Xiu M. Fan Y. Liu Q. Chen S. Wu F. Zhang X. Glucose metabolism, hippocampal subfields and cognition in first episode and never treated schizophrenia. Int. J. Clin. Health Psychol. 2023 23 4 100402 10.1016/j.ijchp.2023.100402 37663043
33 Gao Z. Xiu M. Liu J. Wu F. Zhang X.Y. Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone. Schizophrenia 2023 9 1 17 10.1038/s41537-023-00346-z 36949120
34 Plum L. Schubert M. Brüning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 2005 16 2 59 65 10.1016/j.tem.2005.01.008 15734146
35 Tomasik J. Lago S.G. Vázquez-Bourgon J. Papiol S. Suárez-Pinilla P. Crespo-Facorro B. Bahn S. Association of insulin resistance with schizophrenia polygenic risk score and response to antipsychotic treatment. JAMA Psychiatry 2019 76 8 864 867 10.1001/jamapsychiatry.2019.0304 30942838
36 Freeman L.R. Haley-Zitlin V. Stevens C. Granholm A.C. Diet-induced effects on neuronal and glial elements in the middle-aged rat hippocampus. Nutr. Neurosci. 2011 14 1 32 44 10.1179/174313211X12966635733358 21535919
37 Zhao Z. Ksiezak-Reding H. Riggio S. Haroutunian V. Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr. Res. 2006 84 1 1 14 10.1016/j.schres.2006.02.009 16581231
38 Emamian E.S. Hall D. Birnbaum M.J. Karayiorgou M. Gogos J.A. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat. Genet. 2004 36 2 131 137 10.1038/ng1296 14745448
39 Kapogiannis D. Dobrowolny H. Tran J. Mustapic M. Frodl T. Meyer-Lotz G. Schiltz K. Schanze D. Rietschel M. Bernstein H.G. Steiner J. Insulin-signaling abnormalities in drug-naïve first-episode schizophrenia: Transduction protein analyses in extracellular vesicles of putative neuronal origin. Eur. Psychiatry 2019 62 124 129 10.1016/j.eurpsy.2019.08.012 31590015
40 Wijtenburg S.A. Kapogiannis D. Korenic S.A. Mullins R.J. Tran J. Gaston F.E. Chen S. Mustapic M. Hong L.E. Rowland L.M. Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia. Schizophr. Res. 2019 208 324 330 10.1016/j.schres.2019.01.031 30760413
41 Fünfschilling U. Supplie L.M. Mahad D. Boretius S. Saab A.S. Edgar J. Brinkmann B.G. Kassmann C.M. Tzvetanova I.D. Möbius W. Diaz F. Meijer D. Suter U. Hamprecht B. Sereda M.W. Moraes C.T. Frahm J. Goebbels S. Nave K.A. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012 485 7399 517 521 10.1038/nature11007 22622581
42 Steiner J. Bernstein H.G. Schiltz K. Müller U.J. Westphal S. Drexhage H.A. Bogerts B. Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014 48 287 294 10.1016/j.pnpbp.2012.09.016 23085507
43 Peters A. The selfish brain: Competition for energy resources. Am. J. Hum. Biol. 2011 23 1 29 34 10.1002/ajhb.21106 21080380
44 Veldhuis J.D. Neuroendocrine mechanisms mediating awakening of the human gonadotropic axis in puberty. Pediatr. Nephrol. 1996 10 3 304 317 10.1007/BF00866767 8792395
45 Hwang W.J. Lee T.Y. Kim N.S. Kwon J.S. The role of estrogen receptors and their signaling across psychiatric disorders. Int. J. Mol. Sci. 2020 22 1 373 10.3390/ijms22010373 33396472
46 Gonçalves V.F. Cuperfain A.B. Kennedy J.L. Sex differences in schizophrenia: estrogen and mitochondria. Neuropsychopharmacology 2019 44 1 216 217 10.1038/s41386-018-0228-0 30294000
47 Sinclair D. Purves-Tyson T.D. Allen K.M. Weickert C.S. Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain. Psychopharmacology 2014 231 8 1581 1599 10.1007/s00213-013-3415-z 24481565
48 Cosgrove K.P. Mazure C.M. Staley J.K. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol. Psychiatry 2007 62 8 847 855 10.1016/j.biopsych.2007.03.001 17544382
49 Kulkarni J. Gavrilidis E. Worsley R. Hayes E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs 2012 26 7 549 557 10.2165/11630660-000000000-00000 22626057
50 Brandt N. Fester L. Rune G.M. Neural sex steroids and hippocampal synaptic plasticity. Vitam. Horm. 2020 114 125 143 10.1016/bs.vh.2020.06.001 32723541
51 Rocks D. Kundakovic M.J.J.o.N. Hippocampus‐based behavioral, structural, and molecular dynamics across the estrous cycle. J. Neuroendocrinol. 2023 35 2 e13216 10.1111/jne.13216 36580348
52 Pratchayasakul W. Sa-nguanmoo P. Sivasinprasasn S. Pintana H. Tawinvisan R. Sripetchwandee J. Kumfu S. Chattipakorn N. Chattipakorn S.C. Obesity accelerates cognitive decline by aggravating mitochondrial dysfunction, insulin resistance and synaptic dysfunction under estrogen-deprived conditions. Horm. Behav. 2015 72 68 77 10.1016/j.yhbeh.2015.04.023 25989597
53 Luo M. Zeng Q. Jiang K. Zhao Y. Long Z. Du Y. Wang K. He G. Estrogen deficiency exacerbates learning and memory deficits associated with glucose metabolism disorder in APP/PS1 double transgenic female mice. Genes Dis. 2022 9 5 1315 1331 10.1016/j.gendis.2021.01.007 35873026
54 Redman B. Kitchen C. Johnson K.W. Bezwada P. Kelly D.L. Levels of prolactin and testosterone and associated sexual dysfunction and breast abnormalities in men with schizophrenia treated with antipsychotic medications. J. Psychiatr. Res. 2021 143 50 53 10.1016/j.jpsychires.2021.08.022 34450525
55 Mauvais-Jarvis F. Role of sex steroids in β cell function, growth, and survival. Trends Endocrinol. Metab. 2016 27 12 844 855 10.1016/j.tem.2016.08.008 27640750
56 Filippi S. Vignozzi L. Morelli A. Chavalmane A.K. Sarchielli E. Fibbi B. Saad F. Sandner P. Ruggiano P. Vannelli G.B. Mannucci E. Maggi M. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J. Sex. Med. 2009 6 12 3274 3288 10.1111/j.1743-6109.2009.01467.x 19732305
57 Ribeiro D.L. Pinto M.E. Rafacho A. Bosqueiro J.R. Maeda S.Y. Anselmo-Franci J.A. Taboga S.R. Góes R.M. High-fat diet obesity associated with insulin resistance increases cell proliferation, estrogen receptor, and PI3K proteins in rat ventral prostate. J. Androl. 2012 33 5 854 865 10.2164/jandrol.111.016089 22441765
58 Vignozzi L. Morelli A. Sarchielli E. Comeglio P. Filippi S. Cellai I. Maneschi E. Serni S. Gacci M. Carini M. Piccinni M.P. Saad F. Adorini L. Vannelli G.B. Maggi M. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J. Endocrinol. 2012 212 1 71 84 10.1530/JOE-11-0289 22010203
59 Vigueras-Villaseñor R.M. Rojas-Castañeda J.C. Chávez-Saldaña M. Gutiérrez-Pérez O. García-Cruz M.E. Cuevas-Alpuche O. Reyes-Romero M.M. Zambrano E. Alterations in the spermatic function generated by obesity in rats. Acta Histochem. 2011 113 2 214 220 10.1016/j.acthis.2009.10.004 20149418
60 Fanelli G. Gevi F. Belardo A. Zolla L. Metabolic patterns in insulin-sensitive male hypogonadism. Cell Death Dis. 2018 9 6 653 10.1038/s41419-018-0588-8 29844353
61 Souteiro P. Belo S. Oliveira S.C. Neves J.S. Magalhães D. Pedro J. Bettencourt-Silva R. Costa M.M. Varela A. Queirós J. Freitas P. Carvalho D. Insulin resistance and sex hormone-binding globulin are independently correlated with low free testosterone levels in obese males. Andrologia 2018 50 7 e13035 10.1111/and.13035 29744905
62 Melcangi R.C. Panzica G. Garcia-Segura L.M. Neuroactive steroids: focus on human brain. Neuroscience 2011 191 1 5 10.1016/j.neuroscience.2011.06.024 21704130
63 Reddy D.S. Neurosteroids. Prog. Brain Res. 2010 186 113 137 10.1016/B978-0-444-53630-3.00008-7 21094889
